BMO Capital Markets Issues Pessimistic Forecast for Integra LifeSciences (NASDAQ:IART) Stock Price

Key Points

• BMO Capital Markets cut Integra LifeSciences’ price target from $18 to $15 while maintaining a “market perform” rating, implying 18.3% upside from the prior close.
• Analyst sentiment remains cautious: the stock has a consensus “Reduce” rating and an average target price of $17.86, based on one Buy, five Hold, and two Sell ratings.
• Integra exceeded quarterly expectations, reporting $0.56 in EPS versus the $0.48 estimate and revenue of $418.76 million, while institutional investors own 84.78% of the company.

Integra LifeSciences (NASDAQ:IART - Get Free Report) had its price target decreased by BMO Capital Markets from $18.00 to $15.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a "market perform" rating on the life sciences company's stock. BMO Capital Markets' price target would indicate a potential upside of 18.30% from the company's previous close.

Several other equities analysts have also recently issued reports on the company. Weiss Ratings cut Integra LifeSciences from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday. Citigroup reiterated a "neutral" rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Truist Financial raised Integra LifeSciences to a "hold" rating in a report on Thursday. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating and set a $25.00 price objective on the stock in a research report on Thursday, June 18th. Finally, UBS Group started coverage on shares of Integra LifeSciences in a research note on Tuesday, July 28th. They set a "neutral" rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $17.86.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $12.68 on Monday. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The company's fifty day moving average price is $16.69 and its 200-day moving average price is $15.19. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The firm has a market capitalization of $986.12 million, a P/E ratio of -140.87, a PEG ratio of 0.65 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The company had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, equities research analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

A number of large investors have recently bought and sold shares of IART. Sequoia Financial Advisors LLC lifted its holdings in Integra LifeSciences by 27.4% during the first quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company's stock valued at $134,000 after purchasing an additional 3,059 shares in the last quarter. State of Wyoming increased its stake in shares of Integra LifeSciences by 26.3% during the fourth quarter. State of Wyoming now owns 19,998 shares of the life sciences company's stock worth $248,000 after purchasing an additional 4,168 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Integra LifeSciences during the 2nd quarter worth about $82,000. Integrated Wealth Concepts LLC acquired a new position in shares of Integra LifeSciences during the 2nd quarter worth about $84,000. Finally, Amundi lifted its stake in Integra LifeSciences by 80.8% in the 1st quarter. Amundi now owns 19,430 shares of the life sciences company's stock valued at $183,000 after buying an additional 8,681 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company's products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.